Malta - English - Medicines Authority

pharmascience international ltd lampousas 1, 1095 nicosia , cyprus - deferasirox - dispersible tablet - deferasirox 250 mg - all other therapeutic products

Malta - English - Medicines Authority

pharmascience international ltd lampousas 1, 1095 nicosia , cyprus - deferasirox - dispersible tablet - deferasirox 500 mg - all other therapeutic products

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - deferasirox, quantity: 125 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; povidone; magnesium stearate; colloidal anhydrous silica; lactose monohydrate; crospovidone; croscarmellose sodium - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - deferasirox, quantity: 250 mg - tablet, dispersible - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; povidone; lactose monohydrate; sodium lauryl sulfate; microcrystalline cellulose; magnesium stearate; crospovidone - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - deferasirox, quantity: 500 mg - tablet, dispersible - excipient ingredients: crospovidone; croscarmellose sodium; lactose monohydrate; povidone; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium lauryl sulfate - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Malta - English - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - deferasirox - film-coated tablet - deferasirox 90 mg - all other therapeutic products

Malta - English - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - deferasirox - film-coated tablet - deferasirox 180 mg - all other therapeutic products

Malta - English - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - deferasirox - film-coated tablet - deferasirox 360 mg - all other therapeutic products

Malta - English - Medicines Authority

synthon hispania, s.l. calle castello 1, 08830 sant boi de llobregat, barcelona, spain - deferasirox - film-coated tablet - deferasirox 90 mg - all other therapeutic products

Malta - English - Medicines Authority

synthon hispania, s.l. calle castello 1, 08830 sant boi de llobregat, barcelona, spain - deferasirox - film-coated tablet - deferasirox 360 mg - all other therapeutic products